摘要
BACKGROUND: Research findings indicate that neuropilin-1 plays a critical role in lipid metabolism and obesity-associated insulin resistance; on such a basis, the aim of this study was to explore the effects and working mechanism of neuropilin-1 inhibition on the non-alcoholic fatty liver (NAFLD) disease in high-fat-diet (HFD) induced obese mice. METHODS: Firstly, the pcDNA3.1-NRP-1 recombinant plasmid containing neuropilin-1 (NRP1) gene and NRP1 RNA in-terference plasmid shRNA-NRP1 were successfully constructed. A total of 36 C57BL/6 mice were randomly assigned to 6 groups, blank group, control group, pcDNA3.1 injection group, pcDNA3.1-NRP-1 injection group, pGenesil-1.1 injection group and shRNA-NRP1 injection group. Expression of phospho-PI3K, phospho-AKT, phospho-mTOR and neuropilin-1 in liver was measured as well as body and liver weight, blood glucose, serum transaminases and lipid levels of the mice. RESULTS: The weight and liver mass of HFD fed mice injected with pcDNA3.1-NRP-1 were significantly higher than those from the control group, but their body weight and liver mass decreased significantly after shRNA-NRP1 injection. The results also showed that neuropilin-1 expression can significantly influence the severity of hepatic steatosis in HFD fed mice, decreased serum FPG, LDL, AST, ALT levels and the expression of tumor necrosis factor-a (TNF-a), interleukin-1p (IL -1p), and IL-6 mRNA. In addition, the Neuropilin-1 expression will also influence the p-PI3K, p-AKT and p-mTOR in mice. CONCLUSIONS: This study concluded that the inhibition of neuropilin-1 could improve NAFLD disease by decreas-ing body weight and reduce inflammation in HFD induced obese mice by modulating the PI3K/AKT/mTOR signaling pathway.
学科与关键词
- Leukemia inhibitory factor protects against liver steatosis in nonalcoholic fatty liver disease patients and obese miceYuan, Youwen; Li, Kangli; Teng, Fei; Wang, Weiwei; Zhou, Bing; Zhou, Xuan; Lin, Jiayang; Ye, Xueru; Deng, Yajuan; Liu, Wenhui; Luo, Shenjian; Zhang, Peizhen; Liu, Deying; Zheng, Minghua; Li, Jin; Lu, Yan*; Zhang, Huijie*Journal of Biological Chemistry, 2022, 298(6): 101946.被引 5
- Amelioration of non-alcoholic fatty liver disease by targeting adhesion G protein-coupled receptor F1 (Adgrf1)Wu, Mengyao; Lo, Tak-Ho; Li, Liping; Sun, Jia; Deng, Chujun; Chan, Ka-Ying; Li, Xiang; Yeh, Steve Ting-Yuan; Lee, Jimmy Tsz Hang; Lui, Pauline Po Yee; Xu, Aimin; Wong, Chi-Ming*eLife, 2023, 12: e85131.
- Hepatic Clstn3 Ameliorates Lipid Metabolism Disorders in High Fat Diet-Induced NAFLD through Activation of FXRGuo, Jingyi; Huang, Shangyi; Yi, Qincheng; Liu, Naihua; Cui, Tianqi; Duan, Siwei; Chen, Jiabing; Li, Jiayu; Li, Jun; Wang, Lei*; Gao, Yong*; Nie, Guangning*ACS OMEGA, 2023, 8(29): 26158-26169.
